Mississauga: GSK's AREXVY (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada ...

while adults 60 or older with an underlying health condition should ask about their RSV vaccination options. The vaccine for this population is usually AREXVY. Receiving your vaccine doesn’t only help ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

Earlier this week, British drugmaker GSK received approval in Canada for its RSV vaccine for adults aged between 50 and 59 ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associat ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower respiratory tract disease ...

This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Preliminary data were announced from 2 clinical trials evaluating Arexvy in a broader population of adults at increased for RSV disease.